Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
220
days
Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations
Authors
Xiuning Le; Jie Wang; Yan Yu; Yanqiu Zhao; David Planchard; Bo Gao; Alexander Spira; Jingling Liu; Xingya Li; Shirish Gadgeel; Natasha Leighl; Junqiang Zhang; Hidetoshi Hayashi; Makoto Nishio; Julien Mazieres; Adrianus Johannes de Langen; Maurice Pérol; Kiyotaka Yoh; Martin D. Forster; Yasushi Goto; Maria de Miguel Luken; Fernando Fabio Franco Perez; Quincy Chu; Sagun Parakh; Monique B. Nilsson; Yong Jiang; Tianhua Hu; Cunlin Wang; Nichole Baio; Luna Musib; Zineb Mounir; Marcin Kowanetz; Shirley Wang; Steven Yea; Jerry Hsu; Stuart Lutzker; John V. Heymach; Oscar Juan-Vidal; Jonathan W. RiessShow moreShow less
Affiliations
University of Texas MD Anderson Cancer Center, Houston, TX, USA; Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; Harbin Medical University Cancer Hospital, Harbin, China; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France; Blacktown Cancer and Haematology Centre, Blacktown, NSW, Australia; Virginia Cancer Specialists Research Institute and Next Oncology, Fairfax, VA, USA; Jilin Cancer Hospital, Changchun, China; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henry Ford Cancer Institute, Detroit, MI, USA; Princess Margaret Cancer Centre, Toronto, ON, Canada; Anhui Provincial Hospital, Hefei, China; Kindai University Hospital, Osaka, Japan; Cancer Institute Hospital of JFCR, Tokyo, Japan; Toulouse University Hospital, Toulouse, France; Netherlands Cancer Institute, Amsterdam, the Netherlands; Léon Bérard Center, Lyon, France; National Cancer Center Hospital East, Kashiwa, Japan; UCL Cancer Institute/University College London Hospital NHS Trust, London, UK; National Cancer Center Hospital, Tokyo, Japan; START-Rioja, CIBIR, Hospital Universitario San Pedro, Logroño, Spain; MD Anderson Cancer Center, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, VIC, Australia; Allist Pharmaceuticals, Shanghai, China; ArriVent BioPharma, Inc., Newtown Square, PA, USA; La Fe University and Polytechnic Hospital, Valencia, Spain; UC Davis Comprehensive Cancer Center, Sacramento, CA, USAShow moreShow less
164
days
Chemotherapy enhances cancer vaccine efficacy and expands stem-like TCF1+CD8+ T cells
Authors
Laurine Noblecourt; Amanda Wicki; Ashwin Jainarayanan; Vinnycius Pereira-Almeida; James McAuliffe; Emily Steffke; Silvia Panetti; Hannah Fuchs; Ramiro A. Ramirez-Valdez; Vineethkrishna Chandrasekar; Yanshu Cai; Sanne Boekestijn; Adrian V.S. Hill; Audrey Gerard; Marij J.P. Welters; Sjoerd H. Van der Burg; Isabela Pedroza-Pacheco; Benoit J. Van den Eynde; Carol Sze Ki LeungShow moreShow less
Affiliations
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Albinusdreef, 2, 2333 ZA Leiden, the Netherlands; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Ludwig Institute for Cancer Research, de Duve Institute, UCLouvain, Brussels, Belgium; WEL Research Institute, Brussels, BelgiumShow moreShow less
491
days
A transient MXD4-dependent proliferative pause enables survival of brain micrometastases
Authors
Pedro García-Gómez; Diana Retana; Carolina Hernández-Oliver; Oliva Sánchez; Neibla Priego; Laura Álvaro-Espinosa; Lluís Cordón-Barris; Ana de Pablos-Aragoneses; Juan Vázquez-Cantó; Andrea Rojas; Catalina Vela-Gual; Beatriz Ocaña-Tienda; Samuel Morabito; Anna Pascual-Reguant; Pablo Sanz-Martínez; Manan Krishnamurthy; Ajit Kumar Sharma; Luise Rupp; Antonia Stammberger; Sara Carpintero; Rachel Scott; Carlos Garrido; María Gómez; María Isabel García; Kevin Troulé; Verona Villar-Cerviño; Guillermo Garaulet; Antonio Rodríguez; Srinivas Malladi; Nathan Beckouche; Eduardo Caleiras; Sandra Rodriguez-Perales; Raúl Torres-Ruiz; Fátima Al-Shahrour; Miguel Lafarga; Monica Sivakumar; David A. Moore; Cristina Naceur-Lombardelli; Charles Swanton; Holger Heyn; Helen M. Byrne; Víctor M. Pérez-García; Anish Thomas; Marc Schmitz; Mariam Jamal-Hanjani; Manuel ValienteShow moreShow less
Affiliations
Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Mathematical Oncology Laboratory (MOLAB), University of Castilla-La Mancha, Ciudad Real, Spain; Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Center for Cancer Research, NCI, Bethesda, MD, USA; Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany; Molecular Cytogenetics and Cancer Genome Engineering Lab, Cancer Genomics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK; Histopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Instituto de Neurociencias, Consejo Superior de Investigaciones Científicas & Universidad Miguel Hernández, Sant Joan d’Alacant, Spain; Molecular Imaging Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Department of Molecular Biology, Universidad Autonoma de Madrid, Madrid, Spain; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA; AtmosR, Fuveau, France; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain; Advanced Therapies Unit, Instituto de Investigacion Sanitaria Fundacion Jiménez Díaz, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Santander, Spain; Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, Spain; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Cellular Pathology, University College London Hospitals, London, UK; Department of Oncology, University College London Hospitals, London, UK; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK; Mathematical Institute, University of Oxford, Oxford, UK; National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Red Nacional de Metástasis Cerebral, Madrid, SpainShow moreShow less
322
days
Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis
Authors
Fei Ji; Lei Zheng; Dapeng Chen; Peng Xia; Zhongyu Zou; Wei Liu; Jason Bugno; Emile Z. Naccasha; András Piffkó; Chuangyu Wen; Kangdi Li; Liping Xu; Sean Z. Luo; Xiaona Huang; Jiaai Wang; Chengwei Ju; Bei Liu; Yiyi Ji; Han Li; Steven J. Chmura; Sean P. Pitroda; Hua Laura Liang; Chuan He; Ralph R. WeichselbaumShow moreShow less
Affiliations
Department of Radiation and Cellular Oncology, USA; The Ludwig Center for Cancer Research, University of Chicago, Chicago, IL 60637, USA; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA; Howard Hughes Medical Institute, Chicago, IL 60637, USA; Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA; Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60637, USAShow moreShow less
211
days
Ensemble learning of pathology foundation models for precision oncology
Authors
Xiangde Luo; Xiyue Wang; Feyisope Eweje; Xiaoming Zhang; Juan Luis Gomez Marti; Sarah Cascarino; Sen Yang; Yuchen Li; Ryan Quinton; Jinxi Xiang; Yuanfeng Ji; Zhe Li; Yijiang Chen; Colin Bergstrom; Ted Kim; Francesca Maria Olguin; Kelley Yuan; Matthew Abikenari; Andrew Heider; Sierra Willens; Sanjeeth Rajaram; Robert West; Joel Neal; Adam Schoenfeld; Maximilian Diehn; Chad Vanderbilt; Ruijiang LiShow moreShow less
Affiliations
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA, USA; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Institute for Human-Centered Artificial Intelligence, Stanford, CA, USAShow moreShow less
385
days
Intratumoral Bacillus cereus orchestrates stem-like lymphoid niches to potentiate immunotherapy response in hepatocellular carcinoma
Authors
Chupeng Hu; Wenhua You; Yedi Huang; Yuhan Zhang; Jingying Lu; Jianzhou Yuan; Ruimin Shan; Songmao Li; Ran Li; Qing Li; Minghao Li; Yongqiang Gao; Gao-Jun Teng; Yun ChenShow moreShow less
Affiliations
Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Department of Immunology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, Jiangsu, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, Jiangsu, China; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, Jiangsu, China; State Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; Center of Interventional Radiology & Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of Al Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, ChinaShow moreShow less
FAQ
How long does CANCER CELL take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for CANCER CELL. The fastest paper went from submission to acceptance in 164 days (Chemotherapy enhances cancer vaccine efficacy and expands stem-like TCF1+CD8+ T cells, received 2026-03-31, accepted 2026-09-11); the slowest took 641 days. The average is 315 days and the median is 279 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
